Immune checkpoint blockade for glioblastoma: Preclinical activity of single agent and combinatorial therapy.
David A. Reardon(Dana-Farber Cancer Institute), Gordon J. Freeman(Dana-Farber Cancer Institute), Nancy E. Kohl(United States Military Academy), Amy Sauer(Dana-Farber Cancer Institute), Lei Qin(Dana-Farber Brigham Cancer Center), Scott J. Rodig(Brigham and Women's Hospital), Kristen L. Jones(Oregon Health & Science University), Xiaoyun Liao(Bristol-Myers Squibb (Germany)), Prafulla C. Gokhale(Harvard University), F. Stephen Hodi(Harvard University), Keith L. Ligon(Brigham and Women's Hospital), Jun Zhou(Dana-Farber Cancer Institute), Glenn Dranoff(Dana-Farber Cancer Institute)
Cited by 6
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k